Cargando…

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD

BACKGROUND: Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umecl...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Sally, Maltais, François, Tombs, Lee, Fahy, William A, Vahdati-Bolouri, Mitra, Locantore, Nicholas, Riley, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764300/
https://www.ncbi.nlm.nih.gov/pubmed/29386889
http://dx.doi.org/10.2147/COPD.S145285
_version_ 1783292035363504128
author Singh, Sally
Maltais, François
Tombs, Lee
Fahy, William A
Vahdati-Bolouri, Mitra
Locantore, Nicholas
Riley, John H
author_facet Singh, Sally
Maltais, François
Tombs, Lee
Fahy, William A
Vahdati-Bolouri, Mitra
Locantore, Nicholas
Riley, John H
author_sort Singh, Sally
collection PubMed
description BACKGROUND: Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umeclidinium (UMEC) and long-acting β(2)-agonist vilanterol (VI) separately and in combination on static hyperinflation, exercise endurance time (EET), and their relationship in patients with COPD. METHODS: Patients with moderate-to-severe stable COPD and resting functional residual capacity >120% predicted were randomized to UMEC/VI 62.5/25 μg, UMEC 62.5 μg, VI 25 μg, or placebo for 12 weeks. Inspiratory capacity (IC), residual volume (RV), total lung capacity (TLC), and EET in an endurance shuttle-walk test were measured. In this post hoc analysis, IC/TLC, RV/TLC, and IC were used as hyperinflation markers. RESULTS: After 12 weeks, UMEC/VI and UMEC and VI showed significant improvements in hyperinflation versus placebo when measured by absolute change from baseline in IC/TLC (trough and 3 hours postdose [P≤0.011]). UMEC/VI showed significant improvements versus UMEC and VI in absolute changes in IC/TLC (trough and 3 hours postdose [P≤0.001]). Statistical significance for comparisons with placebo and between treatments for absolute changes in IC and percentage changes in RV/TLC followed similar patterns to those for absolute changes in IC/TLC. UMEC/VI showed significant improvements in EET versus placebo at day 2 and week 12, measured as change from baseline in seconds (P≤0.002) and as a percentage from baseline (P≤0.005). There was a lack of evidence to suggest a correlation between improvements in static hyperinflation and EET at any time point. CONCLUSION: Although the dual bronchodilator UMEC/VI demonstrated greater improvements in static hyperinflation markers than UMEC or VI and significant improvements in exercise endurance, no direct relationship was observed between static hyperinflation and exercise endurance.
format Online
Article
Text
id pubmed-5764300
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57643002018-01-31 Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD Singh, Sally Maltais, François Tombs, Lee Fahy, William A Vahdati-Bolouri, Mitra Locantore, Nicholas Riley, John H Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umeclidinium (UMEC) and long-acting β(2)-agonist vilanterol (VI) separately and in combination on static hyperinflation, exercise endurance time (EET), and their relationship in patients with COPD. METHODS: Patients with moderate-to-severe stable COPD and resting functional residual capacity >120% predicted were randomized to UMEC/VI 62.5/25 μg, UMEC 62.5 μg, VI 25 μg, or placebo for 12 weeks. Inspiratory capacity (IC), residual volume (RV), total lung capacity (TLC), and EET in an endurance shuttle-walk test were measured. In this post hoc analysis, IC/TLC, RV/TLC, and IC were used as hyperinflation markers. RESULTS: After 12 weeks, UMEC/VI and UMEC and VI showed significant improvements in hyperinflation versus placebo when measured by absolute change from baseline in IC/TLC (trough and 3 hours postdose [P≤0.011]). UMEC/VI showed significant improvements versus UMEC and VI in absolute changes in IC/TLC (trough and 3 hours postdose [P≤0.001]). Statistical significance for comparisons with placebo and between treatments for absolute changes in IC and percentage changes in RV/TLC followed similar patterns to those for absolute changes in IC/TLC. UMEC/VI showed significant improvements in EET versus placebo at day 2 and week 12, measured as change from baseline in seconds (P≤0.002) and as a percentage from baseline (P≤0.005). There was a lack of evidence to suggest a correlation between improvements in static hyperinflation and EET at any time point. CONCLUSION: Although the dual bronchodilator UMEC/VI demonstrated greater improvements in static hyperinflation markers than UMEC or VI and significant improvements in exercise endurance, no direct relationship was observed between static hyperinflation and exercise endurance. Dove Medical Press 2018-01-08 /pmc/articles/PMC5764300/ /pubmed/29386889 http://dx.doi.org/10.2147/COPD.S145285 Text en © 2018 Singh et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Singh, Sally
Maltais, François
Tombs, Lee
Fahy, William A
Vahdati-Bolouri, Mitra
Locantore, Nicholas
Riley, John H
Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
title Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
title_full Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
title_fullStr Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
title_full_unstemmed Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
title_short Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
title_sort relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with copd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764300/
https://www.ncbi.nlm.nih.gov/pubmed/29386889
http://dx.doi.org/10.2147/COPD.S145285
work_keys_str_mv AT singhsally relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd
AT maltaisfrancois relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd
AT tombslee relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd
AT fahywilliama relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd
AT vahdatibolourimitra relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd
AT locantorenicholas relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd
AT rileyjohnh relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd